Olodaterol (brand name: Striverdi®) is a bronchodilator belonging to the group of beta-2-symptomimetics. It is used for the symptomatic long-term treatment of COPD, a chronic obstructive pulmonary disease in which the airways are permanently narrowed. It thus helps sufferers to breathe more easily.

It can be used alone or (since 2016) in combination with tiotropium, an anticholinergic.

Use & Indications

Olodaterol is inhaled both alone as a solution and in combination with other active ingredients, always using the Respiramat inhalation device.

This works purely mechanically and does not require any electrical energy, for example from a battery. During use, it generates a spray cloud consisting of very fine droplets that spreads very slowly. In contrast to conventional inhalation devices, this enables a more coordinated intake. Thus, less active ingredient remains in the mouth/throat and most of it reaches the lungs directly for a more targeted intake.

One dose comprises two sprays (2.5 µg/stroke), i.e. it must be sprayed and inhaled twice in succession. This application takes place once a day, always at the same time of day, since the duration of action of olodaterol is 24 hours.

This information applies to both Striverdi® and Spiolto®.


Pharmacodynamics/mechanism of action

Olodaterol acts as a bronchodilator by binding with very high selectivity as well as strong affinity to the beta-2-adrenoceptor - primarily in the lungs - and consequently activating it. After binding to the receptor, it dissociates (dissolves) only slowly, which explains the long-lasting effect of the drug.

Activation of the receptor stimulates adenylate cyclases. This increases the formation of cyclic adenosine monophosphate (cAMP), which then also activates cAMP-dependent protein kinase A (PKA). This leads to the reduction of intracellular Ca2+ through phosphorylation, preventing airway smooth muscle contraction.

Consequently, the increased formation of these two molecules causes bronchodilation by relaxing airway smooth muscle, making it easier for the COPD patient to breathe.

By mimicking endogenous catecholamines (epinephrine, norepinephrine), olodaterol thus exerts bronchodilator as well as partial anti-inflammatory effects as an adrenergic beta-2 agonist.


After inhalation, the maximum plasma concentration of the active substance is reached after 10-20 minutes. Bioavailability is high at 30%, being less than 1% when taken perorally (by mouth). However, it is also dependent on individual lung absorption and how much of the active ingredient is actually inhaled, as any portion swallowed or remaining in the mouth remains insignificant to the effect.

If olodaterol enters the metabolic system, then most of it is excreted in the feces (53%), with a smaller portion (38%) excreted renally.

Drug Interactions

  • Olodaterol in combination with drugs that prolong the QTC interval, such as monoamino oxidase inhibitors, tricyclic antidepressants, corticosteroids, MAO inhibitors, etc., may be enhanced in its effect on the cardiovascular system and lead to cardiovascular problems.
  • When interacted with other adrenergic agents that share the same mechanism, the effect may be mutually potentiated - whereas β-adrenoceptor blockers and olodaterol attenuate each other due to their opposite mechanism of action.
  • Hypokalemia may occur with concomitant therapy of olodaterol with xanthine derivatives, steroids, or nonpotassium-sparing diuretics.


Contraindications & Precautions

Olodaterol must not be used in case of:

  • hypersensitivity to the active substance
  • asthma
  • acute bronchospasm

Caution should be exercised in patients with cardiovascular disease, as well as in patients with prolongation of the QT interval, as strong interactions may occur.

Side effects

Side effects that have been reported in investigations and studies, but have occurred rather rarely, are:

  • Upper respiratory tract infection
  • Bronchitis
  • dizziness
  • back pain
  • Skin rash
  • Hypokalemia

Pregnancy and lactation

Whether or not olodaterol has an effect on the mother-to-be during pregnancy is not yet known due to the lack of studies and the data that depend on them.

However, since the active ingredient is a beta-2 adrenoreceptor agonist and thus exerts a relaxing effect by binding to the beta-2 receptor, application shortly before birth may result in relaxation of the uterine muscles and thus inhibit the birth process. Therefore, its use during pregnancy cannot be recommended for the time being.

Animal studies have now shown that olodaterol and its metabolites can pass into breast milk. Whether this has an effect on the child to be breastfed is pending, as there are no field reports on this yet.

It is assumed, however, that due to the small amount of active ingredient to be taken per day, no effects on the nursing child are to be expected.

Chemical & physical properties

ATC Code R03AC19
Formula C21H26N2O5
Molar Mass (g·mol−1) 386.448 g·mol−1
Physical State solid
CAS Number 868049-49-4
PUB Number 11504295
Drugbank ID DB09080

Editorial principles

All information used for the content comes from verified sources (recognised institutions, experts, studies by renowned universities). We attach great importance to the qualification of the authors and the scientific background of the information. Thus, we ensure that our research is based on scientific findings.
Susann Osmen

Susann Osmen

Susann Osmen studies pharmacy at the University of Vienna and, as a member of the medikamio editorial team, writes detailed texts on the active ingredients, the active components of a drug formulation, through precise research and her expert knowledge. Their mode of action in the body has always fascinated her, which is why she is very interested and highly committed to them.

Mag. pharm. Stefanie Lehenauer

Mag. pharm. Stefanie Lehenauer

Stefanie Lehenauer has been a freelance writer for Medikamio since 2020 and studied pharmacy at the University of Vienna. She works as a pharmacist in Vienna and her passion is herbal medicines and their effects.

The content of this page is an automated and high-quality translation from DeepL. You can find the original content in German here.


Your personal medicine assistent

afgis-Qualitätslogo mit Ablauf Jahr/Monat: Mit einem Klick auf das Logo öffnet sich ein neues Bildschirmfenster mit Informationen über medikamio GmbH & Co KG und sein/ihr Internet-Angebot: medikamio.com/ This website is certified by Health On the Net Foundation. Click to verify.

Search our database for drugs, sorted from A-Z with their effects and ingredients.


All substances with their common uses, chemical components and medical products which contain them.


Causes, symptoms and treatment for the most common diseases and injuries.

The contents shown do not replace the original package insert of the medicinal product, especially with regard to dosage and effect of the individual products. We cannot assume any liability for the correctness of the data, as the data was partly converted automatically. A doctor should always be consulted for diagnoses and other health questions. Further information on this topic can be found here.